Momenta Pharmaceuticals to Present at the BIO CEO & Investor Conference 2008
Posted on: Monday, 4 February 2008, 12:00 CST
CAMBRIDGE, Mass., Feb. 4, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, Chief Executive Officer, will deliver a corporate presentation at the BIO CEO & Investor Conference on Wednesday, February 13th at 11:45 a.m. ET. The conference will be held at the Waldorf Astoria Hotel in New York, NY.
A live audio webcast of the presentation will be available on the "Investors" section of the Company's website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event and will be available through March 13th, 2008.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. Within the Company's discovery program, it is seeking to discover and develop novel therapeutics by applying its technology to better understand sugars' functions in biological processes, with an initial focus in oncology. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley, Investor Relations 617-395-5189
Source: PrimeNewswire
Related Articles
- Momenta Pharmaceuticals to Present At Upcoming Conferences
- Spectrum Pharmaceuticals Presents Data on Lucanthone, a Novel Anticancer Drug, at the Meeting of the American Association of Cancer Research
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- Momenta Pharmaceuticals Initiates Phase 2 Study of Novel Anticoagulant M118
- Hollis-Eden Pharmaceuticals Presents Positive Results With Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer
- Momenta Pharmaceuticals Presents Preclinical Data for Novel Anticoagulant M118 At American College of Cardiology
- Momenta Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2006
- Momenta Pharmaceuticals Files Investigational New Drug Application for Novel Anticoagulant for Acute Coronary Syndromes
- Sonus Pharmaceuticals Presents Preclinical Data on Novel Camptothecin Compound at AACR-NCI-EORTC Cancer Conference
- Momenta Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
 |
 |
User Comments (0)
RSS Feeds